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Abstract. CD151, a member of the tetraspanin family, is 
associated with regulation of migration of normal and tumour 
cells via cell surface microdomain formation. CD151 was 
found in our laboratory to have a prognostic value in pros-
tate cancer and is a promoter of prostate cancer migration 
and invasion. These roles involve association with integrins 
on both cell-cell and cell-stroma levels. Furthermore, CD151 
plays a role in endothelial cell motility. CD151 expression was 
examined in three commonly used prostate cancer cell lines. 
We investigated CD151 expression, angiogenesis (microvessel 
density; MVD) and lymphangiogenesis (lymphatic vessel 
density; LVD) in an orthotopic xenograft model of prostate 
cancer in matched tumours from primary and secondary sites. 
CD151 was found to be heterogeneously expressed across 
different prostate cancer cell lines and the levels of CD151 
expression were significantly higher in the highly tumorigenic, 
androgen-insensitive cells PC-3 and DU-145 compared to the 
androgen-sensitive cell line LNCaP (P<0.05). The majority of 
in vivo xenografts developed pelvic lymph node metastases. 
Importantly, primary tumours that developed metastasis had 
significantly higher CD151 expression and MVD compared to 
those which did not develop metastasis (P<0.05). We identi-
fied, for the first time, that CD151 expression is associated with 
LVD in prostate cancer. These findings underscore the poten-
tial role of CD151 and angiogenesis in the metastatic potential 
of prostate cancer. CD151 has a prognostic value in this mouse 
model of prostate cancer and may play a role in lymphangio-
genesis. CD151 is likely an important regulator of cancer cell 
communication with the surrounding microenvironment.
Introduction
Prostate cancer is known to be a chronic disease and better 
detection and prognostication allowing long-term manage-
ment is needed to improve quality of life for patients. Different 
prostate cancer cell lines express different levels of cluster 
designation (CD) antigens on their cell surface. Cell lines such 
as LNCaP, PC3 and DU145 are derived from metastatic lesions 
and, thus, have metastatic patterns which can be predicted by 
their CD phenotypes (1). The pattern of expression of CD anti-
gens, thus, potentially provides prognostic information (2,3). 
Some of these CD molecules are transmembrane-4-super-
family (TM4SF) members or tetraspanins, a family of 33 
members in mammals (4-6). The exact biochemical functions 
of tetraspanins are still unknown, however, they have been 
linked to various processes including signal transduction 
pathways, cellular activation, proliferation, motility, adhe-
sion, tissue differentiation, angiogenesis, tumour progression 
and metastasis. Most tetraspanins become downregulated in 
metastatic tumours; however, the CD151 glycoprotein was 
identified by Testa et al (7) to be the first tetraspanin member 
to play a role as a promoter of metastasis.
Binding of CD151 to the laminin binding integrins α3β1, 
α6β1, α6β4 and α7β1 promotes extracellular matrix (ECM) 
remodelling and there is evidence of localisation of CD151 and 
α3 integrins at the intercellular junction between endothelial 
cell-tumour cells, leading to tumour cell transendothelial 
migration across secondary sites (8). CD151 is a point of 
motility regulation on both cell-cell and cell-stroma levels 
which involves control of integrin activation and distribution 
(9). The findings from our laboratory show that CD151 has a 
better prognostication value than traditional Gleason grading 
and can distinguish aggressive forms of prostate cancer (10), 
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and that in vitro manipulation of CD151 leads to change in 
prostate cancer migration (11). It is predicted that heightened 
CD151-positivity in prostate cancer cells will lead to more 
progressive disease; we have explored this in a mouse model 
of prostate cancer in the present study.
Materials and methods
Cell lines and reagents. The human prostate cancer cell lines 
PC-3, LNCaP and DU145 were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). Cell 
lines were maintained and propagated as monolayer cultures in 
RPMI-1640 medium (Invitrogen Life Technologies, Carlsbad, 
CA, USA) respectively, with 10% foetal bovine serum (FBS) 
(Invitrogen Life Technologies) and 100 U/ml penicillin and 
100 µg/ml streptomycin (Invitrogen Life Technologies). 
Antibodies used are monoclonal mouse anti-human CD151 anti-
body, 11B1.G4 (IgG2a) a kind gift from Professor L. Ashman's 
laboratory (Newcastle University, NSW, Australia) (12,13), 
monoclonal mouse anti-human β-tubulin antibody (Invitrogen 
Life Technologies), monoclonal rat anti-mouse CD31 antibody 
(MEC 13.3) (BD Pharmigen™; BD Biosciences, San Jose, 
CA, USA) and monoclonal rat anti-mouse LYVE-1 antibody 
(XB-13) (Santa Cruz Biotechnology, Dallas, TX, USA).
Total cellular protein isolation and western blotting. Modified 
radioimmunoprecipitation (RIPA) buffer was used to extract 
proteins from the cells. Medium was removed from cells 
and cells were washed twice with ice-cold PBS before addi-
tion of ice-cold RIPA buffer containing 1X Complete Mini 
EDTA-free protease inhibitor tablet (Roche Diagnostics, 
Castle Hill, NSW, Australia). Protein concentrations of the 
whole cell lysates were determined using the Bradford assay 
(14). Western blot analysis was used to determine CD151 
expression. Proteins were separated by SDS-PAGE. Protein 
bands were then transferred to nitrocellulose paper and incu-
bated with CD151 antibody (Ab) and peroxidase conjugated 
anti-mouse Ab, respectively. Peroxidase linked anti-mouse 
antibody was purchased from Amersham™ (GE Healthcare 
Biosciences, Rydalmere, NSW, Australia). β-tubulin levels 
were used as a loading control. Protein bands were visualized 
after chemiluminescent reaction.
RNA isolation. RNA was isolated using the Rneasy Mini 
kit (Qiagen) according to the manufacturer's instructions. 
RNA quantity was assessed using a UV spectrophotometer 
at A260 nm and RNA quality was determined using the 
A260 nm/A280 nm ratio.
Reverse-transcript PCR and quantitative PCR. RNA was 
extracted from prostate cancer cell lines, LNCaP, PC-3 and 
DU-145 as previously described. cDNA synthesis were 
performed using M-MuLV kit (Invitrogen Life Technologies). 
cDNA samples were then analysed using CD151 (Assay 
ID Hs00388381_m1) and 18S (Assay ID Hs99999901_s1) 
(as control) TaqMan Gene Expression assays (Applied 
Biosystems/Life Technologies). PCR amplification was 
performed in a 25 µl final volume (total 54 ng cDNA per reac-
tion) using Applied Biosystems 7500 real-time PCR system. 
mRNA expression of CD151 was normalized in relation to the 
control 18S expression. Data are expressed as fold difference 
to LNCaP cell line.
In vivo mouse model of prostate cancer. A severe combined 
immunodeficiency (SCID) mouse model orthotopically 
implanted with the human prostate cancer cell line, PC-3 
constitutively expressing a fluorescent marker dsRED was 
used (15). In total, 12 SCID mice were implanted intrapros-
tatically with human PC-3-DsRed cells, as a model of prostate 
cancer metastasis. Cells were inoculated in 0.01 ml PBS into 
the prostate (1x106 cells/mouse). Mice were sacrificed 7 weeks 
after tumour cell inoculation.
The extent of tumour spread was examined by in vivo 
fluorescent imaging. For regular weekly in vivo imaging, the 
mice under study were first denuded of all hair in the region 
of interest. They were then anaesthetised with a 1-5% isoflu-
orane/95% oxygen air mixture and placed under the light for 
imaging. The emission from DsRed was measured using a Fuji 
Film LAS-3000 camera housed alongside an image intensifier 
and light source in a custom built machine. Primary tumour 
volume was calculated using a common ellipsoid estimation 
length x width2 x 0.5 as previously described (16). Upon 
harvesting, mice were anaesthetised and primary tumours 
and regional lymph nodes were removed, weighed and 
processed for histology and immunohistochemical analyses. 
Tissues were fixed in 10% formalin, followed by paraffin 
embedding and sectioning. Mouse organs (spleen, liver and 
kidneys) were also removed and weighed for examination of 
any organ damage.
Immunohistochemistry. For histological analysis of the 
xenograft mouse model, tissue sections (5 µm) were cut from 
formalin-fixed, paraffin-embedded tumour specimens of 
the implanted prostate cancer specimens and neighbouring 
lymph nodes (if tumour was found). Routine haematoxylin 
and eosin (H&E) staining was performed for each specimen 
for histological analysis. CD151, CD31 (angiogenesis marker) 
and LYVE-1 (lymphatic marker) protein expression in tissue 
sections were measured using Dako LSAB+ kit (Dako). CD151, 
CD31 and LYVE-1 stainings were performed as previously 
described (10,15,17,18). Ab used was anti-human CD151 Ab 
(4 µg/ml working concentration), CD31 Ab (diluted 1:10) and 
LYVE-1 Ab (diluted 1:50). Negative control immunostaining 
using isotype control antibody substituted for each primary 
antibody was also performed. Immunostainings were visual-
ized with 3,3'-diaminobenzidine (DAB; Dako Australia Pty, 
Ltd., Campbellfield, VIC, Australia) and sections were then 
counterstained with haematoxylin.
Quantification of endothelial and lymphatic vasculature. 
Staining quantification was performed using light micros-
copy. CD31 and LYVE-1 stainings were analysed on digitised 
colour images and evaluated by counting of positive staining 
vessels. An intratumoural microvessel and lymphatic vessel 
were defined as any brown-stained (DAB immunoperoxidase 
stain with anti-CD31 antigen and anti-LYVE-1 antigen, 
respectively) cell or cell cluster clearly separated from 
adjacent vessels (19). Tumour vascularity was measured as 
microvessel density (MVD) and lymphatic vessel density 
(LVD) in areas containing intense neovascularisation 
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(neovascular ‘hot spot’), as previously described (19,20). The 
step-by-step procedures to identify these ‘hot spots’ were 
previously described (21).
Primary and secondary lesions were examined for MVD 
and LVD. Up to 10 hot spots (depending on tumour size) were 
selected at low magnification (x100) and vessels were counted 
in a representative high magnification (x200). The MVD or 
LVD ratios were calculated as vascular density/(0.74 mm2 for 
each x200 field). The vasculature ratios of primary tumour 
and secondary lymph node metastasis were compared and 
analysed. In addition, mice were also assigned into two groups 
of those that formed metastasis and those without metastasis. 
MVD and LVD of primary tumours of these two groups were 
also compared and analysed.
Statistical analysis. Statistical analysis was carried out using 
independent samples Student's t-tests. All P-values of <0.05 
were considered to indicate a statistically significant result. 
Results are expressed as mean ± standard error of the mean 
(SEM). The statistical tests performed for MVD and LVD 
were two-tailed, equal (F-value >0.05) or unequal variance 
(F-value ≤0.05), Student's t-test. Pearson correlation was 
also performed to examine the relationship between CD151 
staining, MVD, LVD and tumour weights.
Results
CD151 is expressed in commonly used prostate cancer cell 
lines. CD151 is heterogeneously expressed across all prostate 
cancer cell lines investigated. LNCaP, an androgen-responsive 
cell line, expressed low levels of CD151 protein and mRNA 
compared to two androgen-insensitive cell lines, PC-3 and 
DU-145 (Figs. 1 and 2, respectively).
CD151 is a prognostic marker in mouse model of prostate 
cancer. All mice developed primary tumours at the site 
of inoculation (100% tumour take rate) and 8 of 12 (67%) 
mice developed pelvic lymph node metastases. CD151 
expression was investigated via immunohistochemistry 
(Fig. 3). CD151 expression is predominantly localised in 
the cellular membrane and cytosol in prostate cancer cells. 
Weaker nuclear staining can also be seen. CD151 expression 
was examined in the primary and secondary lesions and no 
difference was seen between the two tumour sites (Fig. 4A). 
However, the expression of CD151 in primary tumour speci-
mens from the group of mice forming metastasis was found to 
be significantly higher than in those mice without metastasis 
Figure 1. CD151 protein expressions in commonly used prostate cancer cell 
lines. (A) Western blot analysis of prostate cancer cell lines, LNCaP, PC-3 and 
DU145 showing CD151 and β-tubulin protein expressions. (B) Densitometric 
analysis of CD151 corrected for protein loading using β-tubulin levels. 
Densitometry was performed in 3 separate blots and expressed as a ratio of 
CD151/β-tubulin expression intensity in arbitrary units (AU) (*P<0.05; N=3; 
error bars, SEM).
Figure 2. Relative CD151 mRNA expression in prostate cancer cell lines, 
LNCaP, PC-3 and DU145 cells. Relative expression was normalized to 18S. 
Student's t-test comparing to LNCaP cells to DU145 and PC-3 cells revealed 
2-fold and 3-fold higher CD151 expression, respectively compared to LNCaP 
cells. (*P<0.05, **P<0.001; N=3; error bars, SEM).
Figure 3. Representative areas of immunohistochemical CD151 tissue 
staining from (A) primary lesions, (B) secondary lymph node lesions 
(Original magnification, x200).
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formation (Fig. 4B). There was no evidence of non-specific 
staining in the control slides (data not shown). This confirms 
that CD151 has a prognostic value in this mouse model of 
prostate cancer.
Angiogenesis and lymphangiogenesis markers in mouse 
model of prostate cancer. We next investigated angiogenesis 
and lymphangiogenesis markers. The angiogenesis marker 
CD31 was used as a marker and microvessel density (MVD) 
and was measured in primary and secondary lesions. No 
difference in MVD was detected between primary and 
secondary lesions. However, MVD was significantly higher 
in primary prostatic xenografts forming metastases at nearby 
lymph nodes compared to primary lesions that did not form 
metastasis (Fig. 5). There was no association between tumour 
weight and MVD of the metastasis forming xenografts (data 
not shown).
Lymphatic vessel density (LVD) was not significantly 
different between primary and secondary lesions (Fig. 6) but 
there was a similar trend (P=0.19) toward increased LVD in 
primary xenografts forming metastases compared to those 
that did not form metastasis.
Figure 4. Primary lesions from mice that formed secondary metastases have higher CD151 expression compared to those that did not form metastasis. 
(A) CD151 protein expression of primary xenograft tumours (N=12) and lymph node secondary metastases (N=8). Data presented as log10 integrated optical 
density (IOD). (B) CD151 protein expression (immunohistochemistry) in primary prostate xenograft with (N=8) and without (N=4) metastatic formation. Data 
shown as mean ± SEM. (*P<0.05; error bars, SEM).
Figure 5. Angiogenesis is a prognostic marker in the PC-3 orthotopic xenograft mouse model of prostate cancer. (A) Mean MVD of primary xenograft tumours 
(N=12) and lymph node secondary metastases (N=8). (B) Mean MVD of primary prostate xenograft with (N=8) and without (N=4) metastatic formation. Data 
showing mean ± SEM (*P<0.05; error bars, SEM).
Figure 6. Lymphatic vessel density (LVD) in the PC-3 orthotopic xenograft model. (A) Mean LVD of primary xenograft tumours (N=12) and lymph node 
secondary metastases (N=8). (B) Mean MVD of primary prostate xenograft with (N=8) and without (N=4) metastatic formation. Data showing mean ± SEM.
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MVD and LVD relationships with CD151 expression levels 
and tumour growth. The level of CD151 expression, MVD 
and LVD was not significantly different between primary 
and secondary lesions. The relationships between CD151 
staining, MVD and LVD were examined in primary lesions 
(Table I). CD151 expression was positively correlated with 
LVD (LYVE-1 staining) with statistical significance (r=0.62; 
P=0.03). The association between CD151 and MVD (CD31 
staining) did not reach statistical significance (r=0.48; 
P=0.058) and MVD and LVD were not correlated. MVD, 
LVD and CD151 expression did not correlate with tumour size 
(data not shown). Table II demonstrated that LVD may have a 
prognostic value; 83% of mice with high LVD progressed to 
form lymph node metastases.
Discussion
Tumour metastasis is a multi-factorial process and tumour 
cells are sensitive to local microenvironmental cues that regu-
late normal physiological functions such as wound healing 
and epithelial morphogenetic changes leading to malignant 
behaviour (22). CD151 is heterogeneously expressed across 
prostate cancer cell lines and the level of expression was noted 
to be higher in more highly aggressive cell lines. However, 
it has been shown that both LNCaP and PC-3 cell lines 
express integrin α3β1, which is a major partner of CD151 
in the promotion of motility and metastasis (23). Integrin 
expression profiles between LNCaP and PC-3 cells differ, 
especially α3 integrin where LNCaPs have reduced expres-
sion compared to PC-3 cells which may explain the altered 
level of tumourigenicity between the two cell lines (24). This 
suggests the importance of integrins in invasive behaviour 
of prostate cancer. CD151-α3β1 association is found in most 
tissues that express α3β1 (25,26), which reinforces the impor-
tance of CD151 in the various functions of integrin α3β1. Our 
finding suggests that CD151 correlates with aggressiveness of 
the disease but whether CD151 has a role in transformation 
of androgen-responsive to androgen-irresponsive states cannot 
be concluded and is being explored in our laboratory.
While it is evident that CD151 expression correlates 
more with malignant types of prostate cancer, CD151 may 
have a role in angiogenesis as well as tumour motility and 
invasion. Our finding indicates that angiogenesis predicts 
tumour progression, which is in agreement with other studies 
(20,27-29). Although the exact mechanism is not known, there 
has been some evidence that suggests the role of CD151 in 
blood vessel formation in animal models. CD151 is expressed 
in vascular endothelial cells and associated with integrin β1, 
β3, β4, α2, α3, α5 and α6 chains (30). A study using CD151-
null mice has shown a possible role of CD151 in tumour 
angiogenesis (31). These mice were viable and no phenotypic 
change was reported, however, pathological angiogenesis 
was greatly affected, supporting a pro-angiogenic role for 
CD151 specifically in pathological conditions (31,32). Indeed, 
in animal models of myocardial ischaemia, introduction of 
CD151 via gene delivery improved capillary densities (33,34). 
In vitro studies using endothelial cells have shown that 
CD151-integrin complexes have a role in endothelial cell 
proliferation, morphogenesis and migration, which are impor-
tant in the angiogenesis process (30,35,36). In prostate cancer, 
angiogenesis is associated with progression and prognosis 
(17,20,37-39). 
CD151 involvement in angiogenesis has been demonstrated 
through the discovery of CD151-integrin complex localisation 
within endothelial cells and communication between tumour 
and endothelial cells via CD151, both essential for the forma-
tion of tumour neovascularisation (8,36,40). Absence of CD151 
in mouse lung endothelial cells led to alterations in angiogenic 
ability which was found to be through disruption in association 
with laminin-binding integrins and CD151-null mice also had 
defective pathological angiogenesis (31). Importantly, CD151 
may have a role in regulation of tumour cell-endothelial cell 
dynamics and migrating behaviour of the endothelial cell 
which in turn promotes angiogenesis (40). In order to inves-
tigate the possible link between CD151 and angiogenesis, the 
changes in an angiogenesis marker were observed in a mouse 
model of prostate cancer. In prostate cancer, angiogenesis 
(using CD31 as a marker) was found to be an independent 
prognostic predictor (17). When angiogenesis was examined 
in the initiation and progression of prostate cancer using the 
spontaneous autochthonous transgenic adenocarcinoma of 
the mouse prostate (TRAMP) mouse model, CD31 staining 
revealed changes in angiogenesis patterns from low-grade 
prostate intra-epithelial neoplasia (PIN), high-grade PIN and 
amongst different prostate cancer grades (27). Our results indi-
cate that CD151 expression and angiogenesis was a prognostic 
indicator in the PC-3 orthotopic xenograft mouse model and 
this is not correlated to tumour size.
The role of CD151 in angiogenesis is perhaps through 
assisting communication between tumour cells and endothelial 
cells (40). Many studies have found that CD151-integrin (espe-
cially α3β1 and α6β4) complexes are localised at the tumour 
cell and endothelial cell contact area (8,36,40). Expression 
of CD151 is required for integrin distribution within the 
endothelial intercellular contacts, which in turn promotes 
angiogenesis (31). While cross-talk between tumour cells and 
endothelial cells assisting in transendothelial migration of 
Table I. Pearson correlation analysis of CD151, CD31 and 
LYVE-1 staining of primary PC-3 xenograft tumours.
Primary tissue Pearson correlation P-value
staining comparison (r-value) (two-tailed)
CD151 vs. MVD 0.48 0.058
CD151 vs. LVD 0.62 0.03a
MVD vs. LVD 0.50 0.09
aStatistical significance (P<0.05).
Table II. LVD in relation to metastasis formation in PC-3 
orthotopic xenograft mouse model of prostate cancer.
LVD in  Lymph node 
primary lesions n metastasis (%)
High (> mean value of LVD) 6 5 (83)
Low (< mean value of LVD) 6 3 (50)
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tumour cells is important for angiogenesis, CD151 has been 
found to be a membrane linker, through which other signal-
ling proteins stimulate the important regulator of endothelial 
cell function, endothelial nitric oxide synthase (41). Direct 
CD151 gene delivery into endothelial cells results in increased 
proliferation, migration and tube formation (42). Integrins, 
especially α3β1, have been found to be involved in the induc-
tion of angiogenesis by endothelial cells (43-46). Based on 
this information, it is likely that CD151 promotes pathological 
angiogenesis, via its association with integrin α3β1 and this 
association could be important at tumour or endothelial cells. 
Thus, inhibition of this complex via anti-CD151 agents might 
disrupt angiogenesis formation at either tumour or endothelial 
cells.
Our findings indicated statistically positive relationships 
between CD151 and LVD. Although LVD was not found to 
have prognostic value in this mouse model, the CD151 and 
LVD correlation suggest a possible role of CD151 in lymphan-
giogenesis in prostate cancer. This is particularly relevant in 
the PC-3 orthotopic xenograft model as the lymph nodes are 
the most common sites of metastases (15). This provides a 
basis for further exploration.
In conclusion, the involvement of CD151 in prostate cancer 
migration and metastasis is underscored and demonstrated 
in the present study. Because cell motility and invasion are 
decisive events for tumour metastasis, inhibiting CD151 is 
an attractive approach for inhibition of motility and invasion 
signalling pathway in prostate cancer. The present study 
supports further exploration into the role of CD151 in prostate 
cancer angiogenesis and lymphangiogenesis.
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